New Protocol to Optimize iPS Cells for Genome Analysis of Fibrodysplasia Ossificans Progressiva

Stem Cells. 2015 Jun;33(6):1730-42. doi: 10.1002/stem.1981.

Abstract

Successful in vitro disease-recapitulation using patient-specific induced pluripotent stem cells (iPSCs) requires two fundamental technical issues: appropriate control cells and robust differentiation protocols. To investigate fibrodysplasia ossificans progressiva (FOP), a rare genetic disease leading to extraskeletal bone formation through endochondral ossification, gene-corrected (rescued) iPSC clones (resFOP-iPSC) were generated from patient-derived iPSC (FOP-iPSC) as genetically matched controls, and the stepwise induction method of mesenchymal stromal cells (iMSCs) through neural crest cell (NCC) lineage was used to recapitulate the disease phenotype. FOP-iMSCs possessing enhanced chondrogenic ability were transcriptionally distinguishable from resFOP-iMSCs and activated the SMAD1/5/8 and SMAD2/3 pathways at steady state. Using this method, we identified MMP1 and PAI1 as genes responsible for accelerating the chondrogenesis of FOP-iMSCs. These data indicate that iMSCs through NCC lineage are useful for investigating the molecular mechanism of FOP and corresponding drug discovery.

Keywords: Endochondral ossification; Fibrodysplasia ossificans progressiva; Gene correction; Heterotopic ossification; Induced mesenchymal stromal cells; Induced pluripotent stem cell.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activin Receptors, Type I / metabolism
  • Cell Differentiation / genetics
  • Cell Differentiation / physiology*
  • Cell Lineage / physiology
  • Chondrogenesis / genetics*
  • Gene Expression Regulation / physiology
  • Genome, Human*
  • Humans
  • Induced Pluripotent Stem Cells / cytology*
  • Myositis Ossificans / genetics
  • Myositis Ossificans / therapy*
  • Osteogenesis / genetics
  • Osteogenesis / physiology*

Substances

  • Activin Receptors, Type I